XNAS
KRMD
Market cap137mUSD
Oct 08, Last price
3.00USD
1D
0.67%
1Q
-29.91%
Jan 2017
500.00%
Name
KORU Medical Systems Inc (Pre-Reincorp)
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
KORU Medical Systems, Inc. is dedicated to the development, manufacturing, and commercialization of mobile medical devices, primarily serving the ambulatory infusion market across both the United States and international territories. The company's primary offerings revolve around mechanical infusion solutions, notably their FREEDOM infusion systems. These comprehensive systems encompass components such as the FREEDOM60 and FreedomEdge syringe drivers, alongside specialized HIgH-Flo subcutaneous safety needle sets and precision flow rate tubing. Beyond their product range, KORU Medical also supplies educational content and training materials to healthcare professionals, patients, and patient advocates. The distribution of their products is managed through a combination of direct sales efforts, partnerships with medical device distributors, and online channels. Established in 1980, the firm's corporate headquarters are situated in Chester, New York.
Key people
Chairman of the Board · since 2019
Donald B. Pettigrew
President, Chief Executive Officer · since 2019
Manuel A. Marques
Chief Operating Officer · since 2018
Karen Fisher
Chief Financial Officer, Treasurer · since 2015
Lead Independent Director · since 2018
Director · since 2019
Robert T. Allen
Independent Director · since 2018
James M. Beck
Independent Director · since 2018
Kathy S. Frommer
Independent Director · since 2019
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2017‑02 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||